Beam Therapeutics Inc. (BEAM)


+0.89 (+3.87%)
Symbol BEAM
Price $23.9
Beta 1.614
Volume Avg. 0.85M
Market Cap 1.893B
Shares () -
52 Week Range 22.52-54.3
1y Target Est -
DCF Unlevered BEAM DCF ->
DCF Levered BEAM LDCF ->
ROE -41.67% Strong Sell
ROA -23.25% Sell
Operating Margin -
Debt / Equity 21.60% Neutral
P/E -5.62 Strong Sell
P/B 2.25 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest BEAM news

Mr. John M. Evans M.B.A.
NASDAQ Global Select

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.